USP18 and hepatocellular carcinoma: Subsequent FerroOrange staining and BODIPY 581/591 C11 staining revealed that USP18 knockdown enhanced the sensitivity of HCC-SR cells to sorafenib, which was reversed by NCOA4 knockdown (Fig. 4J and Supplementary Fig. S4G).